Oncology Brothers

Treatment Algorithm series: Acute Myeloid Leukemia (AML) w/ @Anand_88_Patel ✅ Importance of molecular testing ✅ Rx for fit/unfit pts ✅ R/R disease Full discussion: - Oncbrothers.com/algo-AML-2025 - Also on the “Oncology Brothers” podcast #HemeTwitter #OncTwitter @OncUpdates

We are proud to share a remarkable outcome at Roswell Park Comprehensive Cancer Center: 100% of patients who underwent allogeneic transplant in 2024 reached six-month survival. I never thought we would ever see such a statistic in our field. roswellpark.org/newsroom/20250…

You need some data as to how to use dato? Below guide offers a practical way to use Datroway in your clinic! ☑️mucositis ☑️pneumonitis ☑️ocular tox Now that Dato-dxd is approved for both breast and EGFR-mutated NSCLC indications, implementation of best practices is key! 👀…

📢 #MedEd #OncTwitter #RadOnc trainees!! Don’t miss the fantastic online lecture series by @NiuSanford @utswcancer 👏 Here’s a great example: Radiation Oncology 101 👉 youtube.com/watch?v=HAwD15… @ASCO @FionnualaCrowle @malina_ioschici @basu_onco79 @ASridharMD @ElisaAgostinett

Ever wonder why bruises change color? Red → Blue → Green → Yellow → Brown That’s hemoglobin breaking down: 🔴 Oxy Hb → 🔵 Deoxy Hb → 🟢 Biliverdin → 🟡 Bilirubin → 🟤 Hemosiderin Your skin becomes a living chemistry timeline. #Hematology #MedEd

I liked this real world study on pulmonary sarcomatoid carcinomas (PSCs). These are rare lung cancers with a very aggressive phenotype & are often excluded from clinical trials. Data here comports with other RWD studies. My thoughts & questions below!🧵

1/3 INDIRECT HYPERBILIRUBINEMIA Saw a 50M in clinic for isolated indirect hyperbilirubinemia. Known thalassemia trait. His bilirubin has chronically hovered around 3 mg/dL, but 6 months ago jumped to 5–6 and stayed there. Got me thinking about causes of elevated indirect bili.

🤣 Of course apples and oranges... But oligoSBRT has 1-2% G3+ toxicity.

Follow-up results from the POSITIVE Trial regarding breastfeeding after hormone receptor-positive #BreastCancer show no differences in breast cancer related events in women who breastfed compared with those who did not. 👉pubmed.ncbi.nlm.nih.gov/40632989/ @fedrophd @AnnPartridgeMD…

🚨 #BRCA/#HRR mutations have similar prevalence in low- & high-volume mHSPC, but greater impact in low-volume disease. Doublets (ARPi/docetaxel) yield poor outcomes for BRCA pts. Time for tailored therapies 🤔 annalsofoncology.org/article/S0923-… #OncTwitter #MedTwitter @Annals_Oncology

Biggest RWD: Cabo/nivo 1st line #kidneycancer 🔴 N=333, 17 countries & 53 centers @aron_project 🟠 mFU 15.9m, mOS not reached, mPFS 33.7m 🟢 ORR 58%, CR 6% 🟣 Poor prognosis: ECOG, sarcomatoid, brain & bone mets 🔵 ≥ G3 AE 37% (Hypertension & HFS) frontiersin.org/journals/oncol…

Get your steps 👟 in!! New study from @TheLancet Public Health! ⬇️

I wrote for #ASCOConnection about the duality of oncology—the quiet heaviness of being both oncologist and dad. The weight doesn’t go away, but you get better at carrying it—and finding meaning in the middle of the mess. What keeps you grounded? @ASCO lnkd.in/gxZ5Duuv

Treatment Algorithm: This is the algorithm we have used during our discussion w/ @Anand_88_Patel for AML! #OncTwitter #MedTwitter #HemeTwitter @OncUpdates

DESTINY-Gastric04: Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer nejm.org/doi/full/10.10…

In pooled data from 4 pivotal trials (RESONATE, RESONATE-2, iLLUMINATE, HELIOS), baseline statin use in CLL/SLL patients was independently associated with: 🔹 Improved OS (aHR 0.62) 🔹 Longer PFS (aHR 0.74) 🔹 Reduced cancer-specific mortality (aHR 0.39) 🔹 No increases in grade…

When do you test for c-MET? Diagnosis? Disease progression? Answer the polling question below to help us learn from your practice at #BTGLung2025 @OncBrothers @OncoAlert @OncLive

This week we released updates on Cervical CA with a few new approvals since we last covered this topic. A 67yo F with stage IV cervical CA on carbo/taxol/atezo has progression of disease. NGS & IHC are unrevealing. Which of the following is now approved in this setting?

A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. @thanosdimop @PlasmaCellPete globenewswire.com/news-release/2…

We appreciate the feedback on the table we had shared! Made some changes based on the recs/step-up dosing for Epcoritamab (as we also need this for Glofit) 🙏🏽🙏🏽! Here is the updated version 👇👇 #HemeTwitter #OncTwitter #MedTwitter #ChallengingCases